New hope for dialysis patients: drug shows promise in lowering dangerous phosphorus levels
NCT ID NCT00416520
First seen Jan 11, 2026 · Last updated Jun 18, 2026 · Updated 23 times
Summary
This study tested a drug called MCI-196 in 336 adults on dialysis with chronic kidney disease and high phosphorus levels. After a washout period, some patients received MCI-196 and others a placebo to see if the drug could safely lower phosphorus. The goal was to manage a common complication of kidney failure, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Study site
Adelaide, Australia
-
Study site
Nedlands, Australia
-
Study site
Parkville, Australia
-
Study site
St Leonards, Australia
-
Study site
Sydney, Australia
-
Study site
Woolloongabba, Australia
-
Study site
Graz, Austria
-
Study site
Frýdek-Místek, Czechia
-
Study site
HradecKralove, Czechia
-
Study site
Ostrava, Czechia
-
Study site
Prague, Czechia
-
Study site
Tábor, Czechia
-
Study site
Ústí nad Labem, Czechia
-
Study site
Bordeaux, France
-
Study site
Montpelier, France
-
Study site
Paris, France
-
Study site
Aachen, Germany
-
Study site
Aschaffenburg, Germany
-
Study site
Coburg, Germany
-
Study site
Coesfeld, Germany
-
Study site
Darmstadt, Germany
-
Study site
Dieburg, Germany
-
Study site
Dortmund, Germany
-
Study site
Düsseldorf, Germany
-
Study site
Hamburg, Germany
-
Study site
Homberg (Efze), Germany
-
Study site
Langen, Germany
-
Study site
Mannheim-Kafertal, Germany
-
Study site
München, Germany
-
Study site
Potsdam-Babelsberg, Germany
-
Study site
Baja, Hungary
-
Study site
Budapest, Hungary
-
Study site
Kisvárda, Hungary
-
Study site
Veszprém, Hungary
-
Study site
Biella, Italy
-
Study site
Como, Italy
-
Study site
Cremona, Italy
-
Study site
Lecco, Italy
-
Study site
Livorno, Italy
-
Study site
Milan, Italy
-
Study site
Pavia, Italy
-
Study site
Perugia, Italy
-
Study site
Rome, Italy
-
Study site
Ciechanów, Poland
-
Study site
Częstochowa, Poland
-
Study site
Gdansk, Poland
-
Study site
Krakow, Poland
-
Study site
Lodz, Poland
-
Study site
Lublin, Poland
-
Study site
Oświęcim, Poland
-
Study site
Pabianice, Poland
-
Study site
Rybnik, Poland
-
Study site
Sokołów Podlaski, Poland
-
Study site
Starogard Gdański, Poland
-
Study site
Warsaw, Poland
-
Study site
Wejherowo, Poland
-
Study site
Zgierz, Poland
-
Study site
Zielona Góra, Poland
-
Study site
Cape Town, South Africa
-
Study site
Durban, South Africa
-
Study site
Gauteng, South Africa
-
Study site
Johannesburg, South Africa
-
Study site
Port Elizabeth, South Africa
-
Study site
Barcelona, Spain
-
Study site
Oviedo, Spain
-
Study site
Seville, Spain
-
Study site
Glasgow, United Kingdom
-
Study site
Stevenage, United Kingdom
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.